{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-24-000007","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.733577+00:00","generated_at":"2026-06-05T07:16:04.191297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"MoonLake FY 2023 net loss $44.1M; cash $511M; sonelokimab Phase 3 prep advances","bullets":["Cash, cash equivalents and short-term marketable debt securities $511.0M at Dec 31, 2023, up from $496M at Sep 30, 2023.","Net loss for FY 2023 $44.1M, improved from $64.5M in FY 2022.","R&D expenses $31.8M in FY 2023, down from $42.0M in FY 2022.","Completed positive Phase 2 data for sonelokimab in HS and PsA; FDA/EMA feedback supports Phase 3 VELA program in HS.","Raised $85M gross proceeds from at-the-market offerings; cash runway expected to end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-24-000007","json":"https://secwatch.observer/filing/0001821586-24-000007.json","markdown":"https://secwatch.observer/filing/0001821586-24-000007.md","text":"https://secwatch.observer/filing/0001821586-24-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/0001821586-24-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/mnlk-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:16:04.191297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe86a34878426e6e5e51f6046c67748bea12e081","claim":"MoonLake Immunotherapeutics reported the quarter and fiscal year ended December 31, 2023 results: net income $44.1 million.","evidence_excerpt":"MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000182158624000007/0001821586-24-000007-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and fiscal year ended December 31, 2023"},{"label":"Net income","value":"$44.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}